Clinical Trials Browser

Phase 1/2 × Neoplasm, Residual × AST5902 × Clear all

NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Phase 1/2 Unknown

Adenocarcinoma of Lung, Neoplasm, Residual